EW vs BSX vs DXCM
161 measures in 16 categories, one definition each, computed from filings and market data.
EW64.7
Edwards Lifesciences Corporation
Healthcare · Medical - Devices
$86.60 −1.70%$49.9B mkt cap
Score DNA
BSX66.6
Boston Scientific Corporation
Healthcare · Medical - Devices
$44.39 +0.57%$64.3B mkt cap
Score DNA
Price, rebased to 100 three years ago
EW BSX DXCM · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 10 | 0 |
| Insider $ bought, 180d | — | $10.04M | — |
| Congress purchases, 180d | 2 | 15 | 1 |
| Last Congress purchase | 2026-05-01 | 2026-08-18 | 2026-05-01 |
| 13F net change in holders | +46 | — | +14 |
| ETFs adding shares, 30d | 1,345 | 1,212 | 1,144 |
| ETFs trimming, 30d | 1,066 | 1,059 | 1,098 |
| Net ETF funds, 30d | +279 | +153 | +46 |
Valuation
16 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| P/E (TTM) | 49.7x
89th
|
17.5x
19th
|
32.5x
63rd
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | 0.30
7th
|
0.71
27th
|
| Price / sales | 7.7x
82nd
|
3.1x
45th
|
6.5x
78th
|
| Price / book | 4.7x
61st
|
2.6x
41st
|
12.4x
91st
|
| Price / tangible book | 7.2x
54th
|
— | 10.6x
71st
|
| Price / free cash flow | 34.8x
69th
|
17.7x
25th
|
23.1x
42nd
|
| Price / operating cash flow | 29.0x
70th
|
14.2x
26th
|
18.6x
42nd
|
| Enterprise value | $46.4B
93rd
|
$76.4B
95th
|
$31.9B
90th
|
| EV / sales | 7.1x
82nd
|
3.6x
55th
|
6.4x
78th
|
| EV / EBITDA | 29.3x
76th
|
13.2x
39th
|
20.5x
61st
|
| EV / EBIT | 32.7x
73rd
|
17.4x
27th
|
24.6x
48th
|
| EV / free cash flow | 32.3x
56th
|
21.1x
25th
|
22.7x
33rd
|
| Earnings yield | 2.0%
60th
|
5.7%
92nd
|
3.1%
72nd
|
| FCF yield | 2.9%
58th
|
5.6%
85th
|
4.3%
75th
|
| Operating cash flow yield | 3.4%
50th
|
7.0%
82nd
|
5.4%
70th
|
| Graham number (per share) | $26.83
30th
|
$30.54
37th
|
$19.60
22nd
|
Profitability (TTM)
12 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| Gross margin | 78.0%
87th
|
71.2%
73rd
|
62.5%
47th
|
| EBITDA margin | 24.3%
83rd
|
27.6%
92nd
|
31.4%
95th
|
| Operating margin | 28.1%
97th
|
21.5%
92nd
|
22.9%
95th
|
| EBIT margin | 21.8%
92nd
|
20.9%
87th
|
26.1%
95th
|
| Net margin | 15.4%
90th
|
17.5%
93rd
|
20.1%
95th
|
| NOPAT margin | 19.4%
92nd
|
20.4%
93rd
|
17.9%
90th
|
| FCF margin | 22.0%
93rd
|
17.3%
82nd
|
28.3%
98th
|
| Operating cash flow margin | 26.4%
95th
|
21.6%
88th
|
35.2%
100th
|
| R&D / revenue | 16.7%
73rd
|
10.3%
53rd
|
12.2%
64th
|
| SG&A / revenue | 33.8%
25th
|
34.1%
28th
|
27.4%
13th
|
| Stock comp / revenue | 2.6%
47th
|
0.8%
13th
|
3.3%
48th
|
| Effective tax rate | 31.0%
91st
|
5.0%
5th
|
21.9%
79th
|
Returns on capital
11 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| ROE (on average equity) | 9.5%
66th
|
15.5%
85th
|
38.5%
100th
|
| ROA | 7.3%
77th
|
8.5%
82nd
|
14.5%
97th
|
| ROIC | 17.9%
85th
|
11.6%
71st
|
42.9%
97th
|
| ROCE | 11.5%
80th
|
11.3%
78th
|
31.6%
98th
|
| Return on tangible assets | 10.4%
83rd
|
10.1%
82nd
|
18.8%
98th
|
| Cash ROIC (OCF / invested capital) | 24.3%
85th
|
12.2%
66th
|
84.4%
100th
|
| Gross profitability (GP / assets) | 36.6%
52nd
|
33.0%
43rd
|
48.1%
63rd
|
| ROIC, 3-yr average | 28.3%
96th
|
8.2%
71st
|
26.2%
94th
|
| ROIC, 5-yr average | 45.2%
96th
|
6.4%
63rd
|
23.1%
94th
|
| ROE, 5-yr average | 23.0%
96th
|
9.0%
71st
|
22.7%
94th
|
| Incremental ROIC | — | 61.2%
71st
|
-39.1%
25th
|
Growth
17 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| Revenue growth (TTM YoY) | 14.6%
59th
|
13.5%
55th
|
15.5%
64th
|
| Revenue growth (QoQ) | 5.6%
40th
|
4.6%
30th
|
9.8%
60th
|
| Revenue CAGR, 3 yr | 6.3%
30th
|
16.1%
66th
|
15.8%
64th
|
| Revenue CAGR, 5 yr | 5.7%
23rd
|
13.4%
54th
|
18.0%
69th
|
| Gross profit CAGR, 3 yr | 6.4%
25th
|
22.0%
79th
|
14.9%
65th
|
| Operating income CAGR, 3 yr | 4.4%
28th
|
31.6%
72nd
|
36.5%
76th
|
| Net income growth (TTM YoY) | -75.8%
4th
|
46.6%
67th
|
74.9%
88th
|
| Net income CAGR, 3 yr | -10.2%
15th
|
59.0%
85th
|
40.9%
80th
|
| EPS growth (TTM YoY) | -75.3%
4th
|
47.4%
67th
|
82.2%
88th
|
| EPS CAGR, 3 yr | -8.6%
10th
|
58.0%
85th
|
45.5%
80th
|
| EPS CAGR, 5 yr | -5.6%
15th
|
46.5%
95th
|
15.5%
70th
|
| FCF growth (TTM YoY) | 135.8%
83rd
|
9.5%
40th
|
146.1%
87th
|
| FCF CAGR, 3 yr | 28.1%
46th
|
36.5%
58th
|
44.5%
62nd
|
| Operating cash flow CAGR, 3 yr | 22.3%
61st
|
28.7%
65th
|
31.4%
68th
|
| Book value CAGR, 3 yr | 20.7%
86th
|
10.3%
59th
|
11.2%
65th
|
| Dividend CAGR, 3 yr | — | — | — |
| Sustainable growth rate | 9.5%
41st
|
15.5%
78th
|
38.5%
100th
|
Margin history & stability
7 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| Gross margin, 3-yr average | 78.5%
89th
|
65.5%
53rd
|
61.3%
43rd
|
| Operating margin, 3-yr average | 27.2%
98th
|
18.0%
91st
|
18.7%
92nd
|
| Net margin, 3-yr average | 38.8%
100th
|
14.3%
89th
|
16.8%
92nd
|
| FCF margin, 3-yr average | 14.3%
81st
|
15.6%
85th
|
19.5%
96th
|
| Revenue stability (0-1) | 0.77
28th
|
0.95
58th
|
0.99
96th
|
| Earnings stability (0-1) | 0.07
13th
|
0.92
94th
|
0.54
70th
|
| Margin stability (0-1) | 0.98
94th
|
0.93
21st
|
0.94
26th
|
Liquidity (latest quarter)
7 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| Cash & short-term investments | $4.3B
97th
|
$539.0M
78th
|
$1.9B
92nd
|
| Net cash (− = net debt) | $3.5B
100th
|
−$12.1B
3rd
|
$548.6M
97th
|
| Working capital | $5.3B
95th
|
$1.5B
83rd
|
$1.7B
85th
|
| Current ratio | 4.52
68th
|
1.24
7th
|
1.73
20th
|
| Quick ratio | 3.77
70th
|
0.74
7th
|
1.43
28th
|
| Cash ratio (cash + ST investments / current liabilities) | 2.82
72nd
|
0.08
7th
|
0.83
47th
|
| Defensive interval (days) | 585 days
83rd
|
126 days
8th
|
600 days
85th
|
Leverage & solvency (latest quarter)
13 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| Total debt | $704.4M
58th
|
$12.6B
95th
|
$1.4B
82nd
|
| Debt / equity | 0.07
21st
|
0.51
46th
|
0.53
49th
|
| Net debt / equity | −0.33
26th
|
0.48
61st
|
−0.21
37th
|
| Debt / assets | 5.1%
18th
|
27.9%
50th
|
21.7%
43rd
|
| Debt / capital | 6.2%
21st
|
33.6%
46th
|
34.8%
49th
|
| Debt / EBITDA | 0.45
16th
|
2.18
42nd
|
0.90
18th
|
| Net debt / EBITDA | −2.24
8th
|
2.08
50th
|
−0.35
32nd
|
| Interest coverage (EBIT / interest) | — | 12.1x
83rd
|
86.3x
92nd
|
| Cash interest coverage | — | 12.5x
85th
|
116.6x
92nd
|
| Debt payback (years of OCF) | 0.4 yrs
14th
|
2.8 yrs
44th
|
0.8 yrs
21st
|
| Liabilities / assets | 22.7%
17th
|
44.3%
40th
|
59.4%
70th
|
| IS credit model rating | AA+ | A | AAA |
| Implied credit spread (bps) | 65
8th
|
150
30th
|
50
0th
|
Efficiency
11 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| Asset turnover | 0.48
22nd
|
0.48
25th
|
0.72
62nd
|
| Fixed asset turnover | 3.35
16th
|
5.09
55th
|
2.98
12th
|
| Inventory turnover | 1.3
19th
|
2.0
64th
|
2.9
79th
|
| Receivables turnover | 8.9
92nd
|
7.2
70th
|
3.8
8th
|
| Days sales outstanding | 41 days
8th
|
51 days
30th
|
96 days
92nd
|
| Days inventory outstanding | 289 days
81st
|
184 days
36th
|
127 days
21st
|
| Days payables outstanding | 47 days
40th
|
66 days
58th
|
88 days
78th
|
| Cash conversion cycle (days) | 283 days
85th
|
169 days
40th
|
135 days
30th
|
| Capex / revenue | 4.4%
64th
|
4.3%
62nd
|
6.9%
90th
|
| Capex / depreciation | 1.73
79th
|
0.64
45th
|
1.30
74th
|
| Operating expense ratio | 47.7%
29th
|
49.1%
34th
|
39.1%
10th
|
Cash flow & earnings quality
7 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| Operating cash flow / net income | 1.71
56th
|
1.24
30th
|
1.75
63rd
|
| FCF / net income | 1.43
63rd
|
0.99
30th
|
1.41
59th
|
| FCF / operating cash flow | 83.3%
74th
|
80.0%
67th
|
80.3%
69th
|
| Capex / operating cash flow | 16.7%
26th
|
20.0%
33rd
|
19.7%
31st
|
| Accruals ratio | -5.2%
50th
|
-2.0%
85th
|
-10.9%
22nd
|
| Sloan accruals ratio | -0.2%
55th
|
-4.1%
37th
|
-3.7%
38th
|
| Earnings quality score (0-1) | 0.75
4th
|
1.00
48th
|
0.75
4th
|
Scores & forensic checks
15 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| IS score | 65
83rd
|
67
85th
|
81
98th
|
| IS profitability | 64
83rd
|
67
88th
|
83
98th
|
| IS growth | 33
12th
|
68
68th
|
72
79th
|
| IS value | 36
37th
|
50
73rd
|
32
30th
|
| IS momentum | 64
39th
|
93
93rd
|
94
95th
|
| IS risk (safety) | 100
62nd
|
65
42nd
|
100
62nd
|
| IS quality | 82
85th
|
84
90th
|
91
98th
|
| IS balance sheet | 94
98th
|
61
63rd
|
86
80th
|
| IS earnings quality | 75
82nd
|
81
97th
|
53
37th
|
| IS cash flow | 89
97th
|
63
73rd
|
90
100th
|
| Piotroski F-score (0-9) | 6
47th
|
8
83rd
|
9
95th
|
| Altman Z-score | 12.7
88th
|
3.0
50th
|
6.5
70th
|
| Beneish M-score | −2.66
52nd
|
−2.49
73rd
|
−3.13
14th
|
| Ohlson O-score | −10.85
8th
|
−9.32
20th
|
−8.62
30th
|
| IS credit score | 93
88th
|
71
67th
|
95
93rd
|
Size (TTM)
8 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| Market cap | $49.9B
93rd
|
$64.3B
95th
|
$32.5B
92nd
|
| Revenue | $6.5B
88th
|
$21.0B
95th
|
$5.0B
87th
|
| EBITDA | $1.6B
88th
|
$5.8B
95th
|
$1.6B
87th
|
| Net income | $1.0B
90th
|
$3.7B
95th
|
$999.7M
88th
|
| Free cash flow | $1.4B
90th
|
$3.6B
95th
|
$1.4B
88th
|
| Total assets | $13.9B
90th
|
$45.2B
95th
|
$6.5B
83rd
|
| Shareholders' equity | $10.6B
90th
|
$24.9B
97th
|
$2.6B
80th
|
| Employees | 16,000
87th
|
59,000
97th
|
11,050
82nd
|
Price performance
9 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| 1 day | −1.7% | +0.6% | −1.9% |
| 1 week | +1.6% | +3.9% | +2.3% |
| 1 month | −1.9% | +1.9% | −2.1% |
| 3 months | +1.9% | +1.4% | +13.7% |
| 6 months | +6.9% | −30.9% | +34.5% |
| Year to date | +1.5% | −53.1% | +29.3% |
| 1 year | +18.7% | −54.6% | +31.5% |
| 3 years, cumulative | +21.7% | −12.8% | +8.9% |
| 5 years, cumulative | −20.4% | +2.9% | −35.0% |
Technicals
4 measures| Measure | EW | BSX | DXCM |
|---|---|---|---|
| RSI 14 | 49.2 | 52.5 | 50.3 |
| From 52-week high | −10.1% | −58.0% | −7.1% |
| From 52-week low | +19.6% | +7.2% | +59.0% |
| Beta | 0.86 | 0.57 | 1.48 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17